[Neuromidin in mixed vascular and Alzheimer's dementia].

The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer's dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug. The positive effect was seen in 53,3% of patients of the main group.

Cognitive impairments in progression of Parkinson's disease.

A total of 88 patients with progression of Parkinson's disease (PD) were studied. Cognitive impairments (CI) in PD were in most cases progressive in nature, predominantly because of increases in the severity of dysregulatory and neurodynamic disorders, impairments to visuospatial functions, and, in some cases, deficits in nominative speech function. A high frequency of transformation of moderate cognitive impairments to dementia was demonstrated over periods of 2-5 years.

[Cognitive disturbances in the progression of Parkinson's disease].

Cognitive impairment (CD) have been studied in 88 patients with progressive Parkinson's disease (PD). It has been shown that CD in PD have a progressive character mostly due the increase of intensity of dysregulation and neurodynamic disorders, disturbances of visual-spatial functions and, in some cases, insufficiency of nominative speech function. A 2-5 years follow-up revealed the high frequency of transformation of moderate cognitive dysfunction into dementia.